ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.

85,013 comparisons

Most participants first33,758 with no events in either group come last1,501 to 1,520 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Finerenone (BAY94-8862) vs Placebo: Occurence of All-cause Mortality (Full Analysis Set)491 of 3,003

522 of 2,998

-1.1 points

-3.0 to 0.8

6,001NCT04435626

Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%

Finerenone (BAY94-8862) vs Placebo: Occurrence of Total (First and Recurrent) Heart Failure Events479 of 3,003

573 of 2,998

-3.2 points

-5.1 to -1.2

6,001NCT04435626

Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%

Finerenone (BAY94-8862) vs Placebo: Occurrence of the Composite Endpoint of Cardiovascular Death and Total (First and Recurrent) Heart Failure Events624 of 3,003

719 of 2,998

-3.2 points

-5.3 to -1.1

6,001NCT04435626

Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%

10 mg Empagliflozin vs Placebo: deaths from any cause422 of 2,997

427 of 2,991

-0.2 points

-2.0 to 1.6

5,988NCT03057951

EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)

10 mg Empagliflozin vs Placebo: serious adverse events1,436 of 2,996

1,543 of 2,989

-3.7 points

-6.2 to -1.2

5,985NCT03057951

EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)

Fluarix Tetra vs mRNA-1010: Number of Participants With First Episode of RT-PCR Confirmed Centers for Disease Control and Prevention (CDC)-Defined ILI Caused by Any Strain of Influenza Virus22 of 2,979

24 of 2,980

-0.1 points

-0.5 to 0.4

5,959NCT05415462

A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults

Fluarix Tetra vs mRNA-1010: Number of Participants With First Episode of Reverse Transcription Polymerase Chain Reaction (RT-PCR)-Confirmed Protocol-Defined Influenza-Like Illness (ILI) Caused by Any Strain of Influenza Virus54 of 2,979

64 of 2,980

-0.3 points

-1.1 to 0.4

5,959NCT05415462

A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults

Matched Aim 2 Cohort: No SLNB vs Matched Aim 2 Cohort: SLNB: Breast Cancer Specific Mortality36 of 3,965

19 of 1,992

-0.0 points

-0.6 to 0.4

5,957NCT02908178

Comparative Effectiveness of Sentinel Lymph Node Biopsy for Ductal Carcinoma In Situ

Matched Aim 2 Cohort: No SLNB vs Matched Aim 2 Cohort: SLNB: Overall Survival727 of 3,965

287 of 1,992

3.9 points

1.9 to 5.9

5,957NCT02908178

Comparative Effectiveness of Sentinel Lymph Node Biopsy for Ductal Carcinoma In Situ

Matched Aim 2 Cohort: No SLNB vs Matched Aim 2 Cohort: SLNB: Ipsilateral Invasive Breast Cancer Occurrence150 of 3,965

70 of 1,992

0.3 points

-0.8 to 1.2

5,957NCT02908178

Comparative Effectiveness of Sentinel Lymph Node Biopsy for Ductal Carcinoma In Situ

Matched Aim 2 Cohort: No SLNB vs Matched Aim 2 Cohort: SLNB: Treated Recurrence145 of 3,965

78 of 1,992

-0.3 points

-1.3 to 0.7

5,957NCT02908178

Comparative Effectiveness of Sentinel Lymph Node Biopsy for Ductal Carcinoma In Situ

gD2-AS04 Group vs Pooled Group: Number of Subjects With Serious Adverse Events (SAEs)90 of 2,977

100 of 2,978

-0.3 points

-1.2 to 0.6

5,955NCT00224484

Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old

gD2-AS04 Group vs Pooled Group: Number of Subjects With Medically Significant Conditions (MSC)69 of 2,977

73 of 2,978

-0.1 points

-0.9 to 0.6

5,955NCT00224484

Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old

gD2-AS04 Group vs Pooled Group: Number of Subjects With New Onset Chronic Diseases (NOCD)1 of 2,977

0 of 2,978

0.0 points

-0.1 to 0.2

5,955NCT00224484

Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old

Hypotension Decision Support vs Usual Care Group: 30-day Mortality143 of 1,285

511 of 4,667

0.2 points

-1.7 to 2.2

5,952NCT02726620

Decision Support for Intraoperative Low Blood Pressure

Intervention Group vs Historical Control Group: deaths from any cause86 of 3,206

110 of 2,740

-1.3 points

-2.3 to -0.4

5,946NCT04294901

Engaging Patients to Promote Deprescribing

Appy CDS Intervention vs Control: serious adverse events96 of 3,161

109 of 2,779

-0.9 points

-1.8 to 0.0

5,940NCT02633735

EHR-based Decision Support for Pediatric Acute Abdominal Pain in Emergency Care

Telmisartan (TRANSCEND) vs Placebo (TRANSCEND): TRANSCEND. Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction and Non-fatal Stroke384 of 2,954

440 of 2,972

-1.8 points

-3.6 to -0.0

5,926NCT00153101

Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo.

Telmisartan (TRANSCEND) vs Placebo (TRANSCEND): TRANSCEND. Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, Non-fatal Stroke and Hospitalization for Congestive Heart Failure465 of 2,954

504 of 2,972

-1.2 points

-3.1 to 0.7

5,926NCT00153101

Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo.

Telmisartan (TRANSCEND) vs Placebo (TRANSCEND): TRANSCEND. Non-fatal Myocardial Infarction114 of 2,954

145 of 2,972

-1.0 points

-2.1 to 0.0

5,926NCT00153101

Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo.

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=76

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT04435626-733459c1",
        "title": "Finerenone (BAY94-8862) vs Placebo: Occurence of All-cause Mortality (Full Analysis Set)",
        "summary": "491 of 3003 against 522 of 2998; risk difference -1.1 points, 95% interval -3.0 to 0.8; NCT04435626, Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%",
        "record": "/library/comparisons/NCT04435626-733459c1",
        "nct_id": "NCT04435626",
        "kind": "outcome",
        "participants": 6001,
        "risk_difference": {
          "value": -0.010612913881759806,
          "lower": -0.02957128666987499,
          "upper": 0.008348179657930738
        },
        "group_1": "491 of 3,003",
        "group_2": "522 of 2,998",
        "difference": "-1.1 points",
        "interval": "-3.0 to 0.8",
        "trial_title": "Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%"
      },
      {
        "id": "NCT04435626-8ee6dbf7",
        "title": "Finerenone (BAY94-8862) vs Placebo: Occurrence of Total (First and Recurrent) Heart Failure Events",
        "summary": "479 of 3003 against 573 of 2998; risk difference -3.2 points, 95% interval -5.1 to -1.2; NCT04435626, Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%",
        "record": "/library/comparisons/NCT04435626-8ee6dbf7",
        "nct_id": "NCT04435626",
        "kind": "outcome",
        "participants": 6001,
        "risk_difference": {
          "value": -0.031620258771693055,
          "lower": -0.05084363813199356,
          "upper": -0.012382903574507841
        },
        "group_1": "479 of 3,003",
        "group_2": "573 of 2,998",
        "difference": "-3.2 points",
        "interval": "-5.1 to -1.2",
        "trial_title": "Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "None stated"
    }
  ],
  "next": "/api/comparisons/v1?page=77",
  "request_id": "y7jXp60cEJf_etlA"
}
trial-comparisons-2026-03-23-0.1.0Next page

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNone stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Open193,990 genes2026-11-11

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Open611,552 trials2026-11-12

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

For invited accounts.

Opens sequences.conductscience.org

By invitation39,249,078 sequences2026-11-05

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?